Cargando…

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

BACKGROUND AND OBJECTIVE: Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. To evaluate the effect of hepatic impairment on the pharmacokinetics of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piscitelli, Joseph, Chen, Joseph, LaBadie, Robert R., Salageanu, Joanne, Chung, Chin-Hee, Tan, Weiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930943/ https://www.ncbi.nlm.nih.gov/pubmed/35195881 http://dx.doi.org/10.1007/s40261-022-01125-x

Ejemplares similares

Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single‐Dose, Matched Case‐Control Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers
por: Shaik, Naveed, et al.
Publicado: (2021)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib
por: Ruiz-Garcia, Ana, et al.
Publicado: (2020)

The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants
por: Li, Jerry, et al.
Publicado: (2021)

Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018)

Tumor growth inhibition modeling to support the starting dose for dacomitinib
por: Fostvedt, Luke K., et al.
Publicado: (2022)

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

Correction to: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
por: Lin, Swan, et al.
Publicado: (2022)

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment
por: Toussi, Sima S., et al.
Publicado: (2022)

Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations
por: Li, Jerry, et al.
Publicado: (2021)

Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer
por: Tamura, Shuzo, et al.
Publicado: (2018)

Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer
por: Wilson, George D., et al.
Publicado: (2020)

Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry
por: Yamamoto, Yutaro, et al.
Publicado: (2019)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Clinical and Model‐Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells
por: Xu, Lei, et al.
Publicado: (2021)

Drug-induced liver injury associated with dacomitinib: A case report
por: Wang, Xuanxuan, et al.
Publicado: (2022)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report
por: Qiao, Fei, et al.
Publicado: (2022)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
por: Kim, Hyo Song, et al.
Publicado: (2015)

Accessory and stimulating properties of dendritic cells and macrophages isolated from various rat tissues
por: Klinkert, WEF, et al.
Publicado: (1982)

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls
por: Song, Ivy H, et al.
Publicado: (2013)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2021)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Histomorphological and Immunohistochemical Study of Dacomitinib-Induced Ileal Mucositis in Rats with the Possible Protection by Baicalin
por: Kandeel, Samah, et al.
Publicado: (2022)

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2022)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
por: Li, Yibin, et al.
Publicado: (2022)

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors
por: Endersby, Raelene, et al.
Publicado: (2018)

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
por: Zugazagoitia, Jon, et al.
Publicado: (2017)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8k6dpdalhrsfbtpglinhevsfrs